Cidara Therapeutics (NASDAQ:CDTX) Stock

CIDARA THERAPEUTICS INC

Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Inc

The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $350.0 million.

News

CDTX

Reported Earlier, Cidara Therapeutics Prices Upsized Public Offering Of 7,954,546 Shares At $44 Per Share To Raise $350M

RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Outperform and raises the price target from $35 to $75.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $75

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

AMAT

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $50 to $68.

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $68

Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE; platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

Offerings

Cidara Therapeutics Plans To Commence Underwritten Public Offering To Issue And Sell $250M Of Shares

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 339.0% to $1.59 during Monday's regular session. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) stock rose 100.14% to $42.07. The market value of their outstanding shares is at $272.6 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares moved upwards by 85.17% to $0.5. The company's market cap stands at $4.3 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 42.23% to $20.52. The company's market cap stands at $375.3 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 31.24% to $2.83. The company's market cap stands at $66.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 31.08% to $0.32. The company's market cap stands at $30.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares decreased by 46.8% to $2.46 during Monday's regular session. The market value of their outstanding shares is at $433.1 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 33.13% to $42.95. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Quantum BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares decreased by 32.99% to $23.45. The company's market cap stands at $101.7 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock declined by 29.86% to $2.48. The company's market cap stands at $10.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 29.68% to $26.73. The company's market cap stands at $494.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock fell 27.35% to $0.41. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CMPS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INDP

LIMN

LUCY

QNTM

SKYE

WINT

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday.
The Dow traded up 0.02% to 42,216.40 while the NASDAQ gained 0.35% to 19,514.58. The S&amp;P 500 also rose, gaining, 0.23% to 5,981.86.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Monday.
In trading on Friday, health care stocks fell by 0.3%.
Top Headline
The S&amp;P Global US services PMI fell to 53.1 in June versus 53.7 in the previous month, and compared to market expectations of 52.9.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares shot up 386% to $1.76. Dr Ashleys Limited and Impact BioMedical Inc. announced a strategic merger.</li>
<li>Shares of SpartanNash Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>) got a boost, surging 50% to $26.41 after the company announced it will be acquired by C&amp;S Wholesale Grocers.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares were also up, gaining 93% to $40.54 after the company announced positive topline results from its Phase 2b NAVIGATE trial evaluating CD388, a non-vaccine preventative of seasonal influenza.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares dropped 28% to $45.97 after Novo Nordisk reportedly terminated its collaboration with the company.</li>
<li>Shares of Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) were down 26% to $1.23. Lipella Pharmaceuticals announced delisting from Nasdaq Capital Market.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) was down, falling 46% to $2.4901. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $73.05 while gold traded up 0.5% at $3,402.20.
Silver traded up 0.7% to $36.255 on Monday, while copper rose 0.1% to $4.8395.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.26%, while Spain's IBEX 35 Index fell 0.03%. London's FTSE 100 slipped 0.25%, Germany's DAX 40 declined 0.27% and France's CAC 40 fell 0.65% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.13%, Hong Kong's Hang Seng Index gaining 0.67%, China's Shanghai Composite rising 0.65% and India's BSE Sensex falling 0.62%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global US services PMI fell to 53.1 in June versus 53.7 in the previous month, and compared to market expectations of 52.9.</li>
<li>The S&amp;P Global US manufacturing PMI came in unchanged from the previous month at 52 in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46051985/amd-to-rally-more-than-36-here-are-10-top-analyst-forecasts-for-monday">AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

LIPO

SPTN

Crude Oil Falls 1%; US Services PMI Declines In June

WIIM

Cidara Therapeutics shares are trading higher after the company announced its topline results from its randomized, double-blind, placebo-controlled Phase 2b NAVIGATE trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint.

WBB Securities analyst Steve Brozak reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Strong Buy and maintains $45 price target.

Reiteration

WBB Securities Reiterates Strong Buy on Cidara Therapeutics, Maintains $45 Price Target

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $36 to $54.

Needham Maintains Buy on Cidara Therapeutics, Raises Price Target to $54

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) stock is trading over 90% higher on Monday with a session volume of 3.2 million compared to the <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">average volume of 181.7K</a>.
On Monday, the company released topline results from its randomized, double-blind, placebo-controlled Phase 2b NAVIGATE trial evaluating CD388 for preventing seasonal influenza in healthy unvaccinated <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">adults aged 18 to 64</a>.
The study met its primary endpoint, demonstrating a statistically significant prevention efficacy (PE) for each of three dose groups in individuals who received a single dose of CD388 at the beginning of the flu season and were evaluated for laboratory and clinically confirmed <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46048318/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating" rel="noreferrer noopener">influenza over 24 weeks</a>.
The study also met all secondary endpoints, including efficacy at 37.8 and 37.2 degrees Celsius temperature thresholds and maintenance of PE for up to 28 weeks with statistical significance.
Over the same period, CD388 was well-tolerated at all doses, and no unexpected dose-limiting treatment-emergent adverse events were observed.
The highest dose group (450 mg) showed 76.1% prevention efficacy against laboratory and clinically confirmed influenza over 24 weeks, while the 300 mg and 150 mg doses demonstrated 61.3% and 57.7% efficacy, respectively.
All results were statistically significant compared to placebo.
Safety and tolerability data were similar in all arms ,but no safety signals were observed. No drug-related serious adverse events were observed, and treatment-emergent adverse events showed no dose-dependent pattern between CD388 and placebo groups.
Injection site reaction rates were similar across all CD388 dose groups and placebo.
Cidara expects to present additional results from the NAVIGATE trial at upcoming scientific conferences in 2025.
Cidara has submitted an end of Phase 2 meeting request to the FDA to review the Phase 2b results and further discuss the Phase 3 trial design and start time.
In June, Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) announced the results of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle&nbsp;seasonal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">influenza (tNIV) Phase 3 trial</a>.
The study showed that the CIC and flu vaccine candidates induced immune responses similar to those of licensed comparators Nuvaxovid and Sanofi SA's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) <a href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-phase-3-trial" target="_blank" rel="noreferrer noopener">Fluzone HD, respectively</a>.
Both standalone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline).
Price Action: CDTX stock is up 90.7% at $40.08 at last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/24/09/40837263/gsk-reveals-positive-data-from-mid-stage-study-of-seasonal-influenza-mrna-vaccine" target="_blank" rel="noreferrer noopener">GSK Reveals &#8216;Positive&#8217; Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

NVAX

Why Is Cidara Therapeutics Stock Trading Higher On Monday?

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.50% to 42,417.90 while the NASDAQ gained 0.61% to 19,566.92. The S&amp;P 500 also rose, gaining, 0.62% to 6,004.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.7% on Monday.
In trading on Friday, energy stocks fell by 0.1%.
Top Headline
Shares of FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) gained around 5% on Monday after the company posted results for the third quarter.
The company reported quarterly sales of $585.52 million, surpassing analyst expectations of $580.50 million and representing a 5.9% year-over-year gain.
The company reported quarterly adjusted earnings per share of $4.27, missing the street view of $4.29.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares shot up 306% to $1.5001. Dr Ashleys Limited and Impact BioMedical Inc. announced a strategic merger.</li>
<li>Shares of Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) got a boost, surging 139% to $0.6464 after tumbling 18% on Friday.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares were also up, gaining 91% to $40.08 after the company announced positive topline results from its Phase 2b NAVIGATE trial evaluating CD388, a non-vaccine preventative of seasonal influenza.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) shares dropped 50% to $2.6741.</li>
<li>Shares of Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) were down 32% to $1.13. Lipella Pharmaceuticals announced delisting from Nasdaq Capital Market.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) was down, falling 47% to $2.44. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $72.94 while gold traded up 0.3% at $3,397.20.
Silver traded up 0.6% to $36.235 on Monday, while copper rose 0.3% to $4.8495.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.3%, while Spain's IBEX 35 Index rose 0.2%. London's FTSE 100 slipped 0.2%, Germany's DAX 40 declined 0.2% and France's CAC 40 fell 0.6% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.13%, Hong Kong's Hang Seng Index gaining 0.67%, China's Shanghai Composite rising 0.65% and India's BSE Sensex falling 0.62%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global US services PMI fell to 53.1 in June versus 53.7 in the previous month, and compared to market expectations of 52.9.</li>
<li>The S&amp;P Global US manufacturing PMI came in unchanged from the previous month at 52 in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46051985/amd-to-rally-more-than-36-here-are-10-top-analyst-forecasts-for-monday">AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

SANW

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

<h3>Gainers</h3>
<ul>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock increased by 141.3% to $0.65 during Monday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 104.55% to $0.74. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares moved upwards by 66.84% to $35.07. The company's market cap stands at $272.6 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock moved upwards by 40.78% to $20.64. The company's market cap stands at $96.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares moved upwards by 33.18% to $0.59. The market value of their outstanding shares is at $18.4 million. </li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) stock increased by 23.13% to $49.71. The market value of their outstanding shares is at $11.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares declined by 35.2% to $3.0 during Monday's pre-market session. The company's market cap stands at $433.1 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares declined by 21.39% to $5.44. The company's market cap stands at $1.3 billion. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares decreased by 18.19% to $3.51. The market value of their outstanding shares is at $7.0 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 17.13% to $53.22. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.13% to $0.27. The company's market cap stands at $3.8 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 13.32% to $3.06. The market value of their outstanding shares is at $10.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARM

EXEL

FBRX

PCSA

SSII

TCRT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<ul>
<li>The study met its primary and all secondary efficacy endpoints for all dose groups</li>
<li>Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo</li>
<li>CD388 was well-tolerated with no safety signals observed</li>
<li>End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA)</li>
</ul>

Cidara Therapeutics Announces Topline Results From Its Phase 2B NAVIGATE Trial Of CD388 For Seasonal Influenza In Healthy Unvaccinated Adults Aged 18 To 64, The Study Met Its Primary Endpoint, Demonstrating A Statistically Significant Prevention Efficacy For Each Of Three Dose Groups

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $41.

Initiation

HC Wainwright & Co. Assumes Cidara Therapeutics at Buy, Announces Price Target of $41

Cantor Fitzgerald analyst Eric Schmidt reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeuticsto Overweight

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $35 to $36.

Needham Maintains Buy on Cidara Therapeutics, Raises Price Target to $36

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $47 price target.

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

Management

Press Releases

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Cidara Therapeutics to Participate in The Citizens Life Sciences Conference

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

Comments

Cidara Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL